VICTYKRI Trademark

Trademark Overview

On Friday, May 24, 2019, a trademark application was filed for VICTYKRI with the United States Patent and Trademark Office. The USPTO has given the VICTYKRI trademark a serial number of 88445466. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 3, 2023. This trademark is owned by Bristol-Myers Squibb Company. The VICTYKRI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical...
victykri

General Information

Serial Number88445466
Word MarkVICTYKRI
Filing DateFriday, May 24, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 3, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 7, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 10, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Monday, July 3, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 3, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, December 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 6, 2022SOU EXTENSION 5 GRANTED
Monday, November 28, 2022SOU EXTENSION 5 FILED
Monday, December 5, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 28, 2022SOU TEAS EXTENSION RECEIVED
Thursday, May 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 24, 2022SOU EXTENSION 4 GRANTED
Tuesday, May 24, 2022SOU EXTENSION 4 FILED
Tuesday, May 24, 2022SOU TEAS EXTENSION RECEIVED
Saturday, December 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 2, 2021SOU EXTENSION 3 GRANTED
Thursday, December 2, 2021SOU EXTENSION 3 FILED
Thursday, December 2, 2021SOU TEAS EXTENSION RECEIVED
Friday, June 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 2, 2021SOU EXTENSION 2 GRANTED
Wednesday, June 2, 2021SOU EXTENSION 2 FILED
Wednesday, June 2, 2021SOU TEAS EXTENSION RECEIVED
Friday, December 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 2, 2020SOU EXTENSION 1 GRANTED
Wednesday, December 2, 2020SOU EXTENSION 1 FILED
Wednesday, December 2, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, June 2, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 7, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 7, 2020PUBLISHED FOR OPPOSITION
Wednesday, March 18, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, February 29, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 21, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 21, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, February 21, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 21, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 21, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, February 22, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 21, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 21, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 21, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 21, 2019NON-FINAL ACTION E-MAILED
Wednesday, August 21, 2019NON-FINAL ACTION WRITTEN
Wednesday, August 14, 2019ASSIGNED TO EXAMINER
Monday, June 10, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 28, 2019NEW APPLICATION ENTERED

Related Keywords

victykri diseases pharmaceutical preparations disorders anti immune cancer system treatment human